Document Detail

A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis.
MedLine Citation:
PMID:  23292116     Owner:  NLM     Status:  Publisher    
PURPOSE: Methotrexate (MTX) is one of the most widely studied and effective therapeutics agents available to treat many solid tumors, hematologic malignancies, and autoimmune diseases such as rheumatoid arthritis; however, the poor pharmacokinetic and narrow safety margin of the drug limits the therapeutic outcomes of conventional drug delivery systems. For an improved delivery of MTX, several pathophysiological features such as angiogenesis, enhanced permeability and retention effects, acidosis, and expression of specific antigens and receptors can be used either as targets or as tools for drug delivery. METHODS: There are many novel delivery systems developed to improve the pitfalls of MTX therapy ranged from polymeric conjugates such as human serum albumin, liposomes, microspheres, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, polymeric micelles, in situ forming hydrogels, carrier erythrocyte, and nanotechnology-based vehicles such as carbon nanotubes, magnetic nanoparticles, and gold nanoparticles. Some are further modified with targeting ligands for active targeting purposes. RESULTS: Such delivery systems provide prolonged plasma profile, enhanced and specific activity in vitro and in vivo in animal models. Nevertheless, more complementary studies are needed before they can be applied in human. CONCLUSION: This review deals with the challenges of conventional systems and achievements of each pharmaceutical class of novel drug delivery vehicle.
Samira Sadat Abolmaali; Ali Mohammad Tamaddon; Rassoul Dinarvand
Related Documents :
23881926 - Phase iii trials of targeted anti-cancer therapies: redesigning the concept.
24164196 - Recent advances in the discovery and development of novel hiv-1 nnrti platforms (part i...
23738076 - Mri-guided focused ultrasound as a new method of drug delivery.
23416056 - A functional variomics tool for discovering drug-resistance genes and drug targets.
15508776 - Malaria drug-susceptibility testing. hrp2-based assays: current data, future perspectives.
7569676 - Preclinical drug metabolism programs for food-producing animals.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-6
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Pharmaceutical Nanotechnology and Biomaterials Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345, Shiraz, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of HNF4? genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in...
Next Document:  (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenes...